AstraZeneca’s response to the COVID-19 (novel coronavirus) outbreak is consistent with our values to follow the science, put patients first and do the right thing. Our priorities are to ensure the continued supply of our medicines to patients, and to safeguard the health and wellbeing of all our employees and communities.
Bringing science to patients, creating value for Britain
6,500 employees at 5 sites across the UK (as of May 2019)
9% of total pharmaceutical sector employment with a further 39,000 UK jobs supported including Research and Development, Manufacturing, Supply, Sales and Marketing
At the centre of what we do
Our purpose is to push the boundaries of science to deliver lifechanging medicines for patients. We partner with the scientific community to discover and develop these innovative treatments. We work with the NHS in areas such as patient pathway re-design, data, precision medicine and genomics. We are dedicated to collaborating with the NHS to make sure patients have access to the cutting-edge treatments they need. By using precision medicine in ~90% of our clinical pipeline, we aim to tailor new and existing treatments to the needs of individual patients through diagnostic tests.
In the future of UK science
We are investing over £500m in our future global HQ and strategic R&D centre in Cambridge. We have also invested £220m in new manufacturing, warehousing and infrastructure improvements at our Macclesfield campus between 2015-18, representing a spend of over £1m per week. This is the largest medicines manufacturing site in the UK.
At AstraZeneca, science is at the core of everything we do. Read about our latest progress in cardiovascular, respiratory and other core therapy areas.
Be among our employees who continue to make us an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals.
We publish information about the registration and results of all new and ongoing clinical trials for all products in all phases on our dedicated website. For healthcare professionals.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to AstraZeneca on 0800 783 0033 or via https://aereporting.astrazeneca.com
VVPM ID: GB-21240 Date of Prep: April 2020